DrugPatentWatch Database Preview
Details for Patent: 5,886,035
Which drugs does patent 5,886,035 protect, and when does it expire?
Patent 5,886,035 protects ZIOPTAN and is included in one NDA.
This patent has nineteen patent family members in thirteen countries.
This patent has nineteen patent family members in thirteen countries.
Summary for Patent: 5,886,035
| Title: | Difluoroprostaglandin derivatives and their use |
| Abstract: | A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like. |
| Inventor(s): | Shirasawa; Eiichi (Ikoma, JP), Kageyama; Masaaki (Ikoma, JP), Nakajima; Tadashi (Ikoma, JP), Nakano; Takashi (Yokohama, JP), Mori; Nobuaki (Yokohama, JP), Sasakura; Hideshi (Yokohama, JP), Matsumura; Yasushi (Yokohama, JP), Morizawa; Yoshitomi (Yokohama, JP) |
| Assignee: | Asahi Glass Company Ltd. (Tokyo, JP) Santen Pharmaceutical Co., Ltd. (Osaka, JP) |
| Application Number: | 08/993,017 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 5,886,035 |
|
Patent Claim Types: see list of patent claims | Compound; Use; |
Drugs Protected by US Patent 5,886,035
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oak Pharms Inc | ZIOPTAN | tafluprost | SOLUTION/DROPS;OPHTHALMIC | 202514-001 | Feb 10, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 5,886,035
Non-Orange Book US Patents Family Members for Patent 5,886,035
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 5,985,920 | Difluoroprostaglandin derivatives and their use | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 5,886,035
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 225770 | ➤ Sign Up | |||
| Canada | 2225761 | ➤ Sign Up | |||
| China | 1108289 | ➤ Sign Up | |||
| China | 1187486 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
